Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal
- PMID: 21470204
- PMCID: PMC3229765
- DOI: 10.1111/j.1476-5381.2011.01406.x
Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal
Abstract
Despite years of neurobiological research that have helped to identify potential therapeutic targets, we do not have a reliable pharmacological treatment for alcoholism. There are a range of possible explanations for this failure, including arguments that alcoholism is a spectrum disorder and that different population subtypes may respond to different treatments. This view is supported by categorisations such as early- and late-onset alcoholism, whilst multifactorial genetic factors may also alter responsivity to pharmacological agents. Furthermore, experience of alcohol withdrawal may play a role in future drinking in a way that may distinguish alcoholism from other forms of addiction. Additionally, our neurobiological models, based largely upon results from rodent studies, may not mimic specific aspects of the human condition and may reflect different underlying phenomena and biological processes from the clinical pattern. As a result, potential treatments may be targeting inappropriate aspects of alcohol-related behaviours. Instead, we suggest a more profitable approach is (a) to identify well-defined intermediate behavioural phenotypes in human experimental models that reflect defined aspects of the human clinical disorder and (b) to develop animal models that are homologous with those phenotypes in terms of psychological processes and underlying neurobiological mechanisms. This review describes an array of animal models currently used in the addiction field and what they tell us about alcoholism. We will then examine how established pharmacological agents have been developed using only a limited number of these models, before describing some alternative novel approaches to achieving homology between animal and human experimental measures.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Similar articles
-
Pharmacological validation of a new animal model of alcoholism.J Neural Transm (Vienna). 2000;107(6):669-80. doi: 10.1007/s007020070068. J Neural Transm (Vienna). 2000. PMID: 10943907
-
Genetic variation and brain gene expression in rodent models of alcoholism implications for medication development.Int Rev Neurobiol. 2010;91:129-71. doi: 10.1016/S0074-7742(10)91005-2. Int Rev Neurobiol. 2010. PMID: 20813242 Review.
-
The challenge of studying parallel behaviors in humans and animal models.Curr Top Behav Neurosci. 2013;13:611-45. doi: 10.1007/7854_2011_133. Curr Top Behav Neurosci. 2013. PMID: 21671191 Review.
-
Medications for substance use disorders.Soc Work Public Health. 2013;28(3-4):264-78. doi: 10.1080/19371918.2013.759031. Soc Work Public Health. 2013. PMID: 23731419 Free PMC article. Review.
-
[Medicinal plants in the phytotherapy of alcohol or nicotine addiction. Implication for plants in vitro cultures].Przegl Lek. 2013;70(10):869-74. Przegl Lek. 2013. PMID: 24501814 Review. Polish.
Cited by
-
Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2.Neuropsychopharmacology. 2014 Jun;39(7):1674-84. doi: 10.1038/npp.2014.14. Epub 2014 Jan 23. Neuropsychopharmacology. 2014. PMID: 24452391 Free PMC article.
-
Ethanol Exposure History and Alcoholic Reward Differentially Alter Dopamine Release in the Nucleus Accumbens to a Reward-Predictive Cue.Alcohol Clin Exp Res. 2018 Jun;42(6):1051-1061. doi: 10.1111/acer.13636. Epub 2018 Apr 30. Alcohol Clin Exp Res. 2018. PMID: 29602178 Free PMC article.
-
Chronic Nicotine Exposure Initiated in Adolescence and Unpaired to Behavioral Context Fails to Enhance Sweetened Ethanol Seeking.Front Behav Neurosci. 2017 Aug 17;11:153. doi: 10.3389/fnbeh.2017.00153. eCollection 2017. Front Behav Neurosci. 2017. PMID: 28860980 Free PMC article.
-
Tigecycline Reduces Ethanol Intake in Dependent and Nondependent Male and Female C57BL/6J Mice.Alcohol Clin Exp Res. 2016 Dec;40(12):2491-2498. doi: 10.1111/acer.13251. Epub 2016 Nov 14. Alcohol Clin Exp Res. 2016. PMID: 27859429 Free PMC article.
-
Testing pharmacotherapies for alcohol use disorder with cue exposure paradigms: A systematic review and quantitative synthesis of human laboratory trial methodology.Alcohol Clin Exp Res (Hoboken). 2023 Sep;47(9):1629-1645. doi: 10.1111/acer.15143. Epub 2023 Jul 23. Alcohol Clin Exp Res (Hoboken). 2023. PMID: 37423771 Free PMC article. Review.
References
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington, DC: American Psychiatric Press; 1994.
-
- Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156:1758–1764. - PubMed
-
- Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–2017. - PubMed
-
- Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65:135–144. - PMC - PubMed
-
- Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997;132:104–106. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials